Friday, August 14, 2026 delivered a fresh slate of Wall Street upgrades that spanned data center real estate, media, e-commerce, memory semiconductors and rare-disease biotech. That spread matters because the macro backdrop remains restrictive. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% on July 29, 2026, and the CME Group FedWatch tool now assigns roughly an 80% probability to no rate cuts through 2026. With policy on hold, single-name catalysts — new analyst calls, mergers, product cycles and earnings surprises — continue to drive most of the action. The five names below all received notable Buy-equivalent upgrades or initiations on August 14 and screen as candidates worth watching heading into Monday's session.
Digital Realty Trust (DLR) — Data center REIT with AI capacity tailwinds
Digital Realty Trust, the global data center REIT that leases colocation and interconnection capacity to hyperscalers and enterprises, drew a notable upgrade on August 14. HSBC analyst Phani Kanumuri lifted the stock from Hold to Buy with a $240 price target, up from $210, marking a full reversal of HSBC's April 27, 2026 downgrade to Hold. The call cited stronger visibility on data center demand from AI workloads and better lease economics on new capacity coming online.
Shares traded at $200.20 on August 14, up 1.32%, with a market cap of $74.1 billion and a trailing P/E of 96.71. The 52-week range is $146.23 to $208.14. Consensus is Strong Buy, with 10 of 11 tracked analysts bullish, an average target of $226.91, a median of $227, a high of $250 and a low of $197.
Risks: Data center supply is ramping industry-wide, power and land constraints add execution risk in key markets, and the stock's premium multiple leaves little cushion if leasing pace slows. Barclays analyst Brendan Lynch maintained an Equal-Weight rating with a $197 target on July 1, 2026, arguing valuation already reflects the AI thesis.
Fox Corporation (FOXA) — Double upgrade on Roku deal
Fox Corporation, the media company that owns Fox News, Fox Sports, the Fox broadcast network and Tubi, received a rare same-day double upgrade on August 14. JPMorgan analyst David Karnovsky raised the stock from Neutral to Overweight with an $82 December 2027 price target, up from $70, arguing the company is firing on all cylinders at both core Fox and through its pending acquisition of Roku. Wells Fargo analyst Steven Cahall separately upgraded FOXA from Equal-Weight to Overweight with an $80 target, up from $65.
Shares traded at $68.71 on August 14, up 4.99%, with a market cap of $30.1 billion and a trailing P/E of 16.05. The 52-week range is $48.34 to $76.39. Consensus is Buy, with 4 of 8 tracked analysts bullish and 4 neutral, an average target of $74.12, a median of $77.50, a high of $82 and a low of $60.
Risks: The Roku acquisition adds integration and regulatory execution risk, linear TV ad pricing remains soft, and sports rights costs continue to escalate. Barclays analyst Kannan Venkateshwar maintained an Equal-Weight rating with a $60 target on June 15, 2026, reflecting a more cautious view on cord-cutting exposure.
Wayfair (W) — E-commerce turnaround gains a believer
Wayfair, the online home goods retailer that has spent the past two years cutting fixed costs and rationalizing its supplier base, saw Bernstein analyst Nikhil Devnani upgrade the stock from Market Perform to Outperform on August 14 with a $125 price target, up from $100. Bernstein said second-quarter earnings left it more constructive on U.S. eCommerce and that Wayfair's cost discipline and repeat revenue beats justify a higher multiple. UBS reiterated a Buy on August 5 with a $156 target, and Citigroup, Truist, Evercore ISI, Guggenheim and Wells Fargo all raised targets after Q2 results.
Shares traded at $102.02 on August 14, up 0.88%, with a market cap of $14.0 billion and no meaningful trailing P/E given negative twelve-month earnings. The 52-week range is $55.60 to $119.98. Consensus is Buy, with 9 of 13 tracked analysts bullish, an average target of $125.15, a median of $130, a high of $156 and a low of $92.
Risks: Home furnishings demand remains housing-turnover sensitive, promotional activity across peers continues to pressure margins, and the company still needs to prove durable GAAP profitability. RBC Capital analyst Steven Shemesh maintained a Sector Perform rating with a $92 target on August 5, 2026, viewing the recovery as more cyclical than structural.
Micron Technology (MU) — Memory upcycle keeps drawing bulls
Micron Technology, the DRAM and NAND memory maker whose high-bandwidth memory products power AI accelerators, was upgraded from Neutral to Buy at New Street Research on August 14 with a $1,250 price target. The call comes after a broad wave of price-target hikes in late June following Micron's blockbuster fiscal Q3 report and management's guidance for very high revenue and record gross margins in the current quarter, tied to tight HBM3E supply and pricing power.
Shares traded at $965.39 on August 14, up 1.64%, with a market cap of $1.09 trillion and a trailing P/E of 21.83. The 52-week range is $113.46 to $1,255.00. Consensus is Strong Buy, with 16 of 17 tracked analysts bullish, an average target of $1,570.59, a median of $1,525, a high of $2,000 and a low of $1,100.
Risks: Memory is a historically cyclical business, HBM competition from Samsung and SK Hynix is intensifying, and the stock's parabolic run leaves it vulnerable to any hint of order pull-ins. Goldman Sachs analyst James Schneider maintained a Neutral rating at $1,100 on June 25, 2026, arguing the current cycle is closer to peak than early innings.
Krystal Biotech (KRYS) — Rare-disease franchise gets top-decile initiation
Krystal Biotech, the commercial-stage rare-disease biotech behind Vyjuvek, the first approved topical gene therapy for dystrophic epidermolysis bullosa, was initiated at Outperform with a $400 price target by RBC Capital on August 14. The call anchors on Vyjuvek's expanding U.S. label, international launches, and a pipeline that extends the redosable HSV-1 delivery platform into new indications including cystic fibrosis lung disease and aesthetic dermatology.
Shares traded at $330.09 on August 14, up 0.53%, with a market cap of $9.7 billion and a trailing P/E of 41.34. The 52-week range is $136.73 to $382.54. Consensus is Strong Buy, with all 9 tracked analysts bullish, an average target of $350.11, a median of $361, a high of $403 and a low of $284.
Risks: Vyjuvek concentration is high, international pricing negotiations can drag reimbursement timing, and pipeline readouts introduce clinical binary risk. Guggenheim analyst Debjit Chattopadhyay carries the low $284 target with a Buy rating dated February 25, 2026, a reminder that even bulls disagree on valuation range.
Found this helpful? Share it with others.